<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9117">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05704920</url>
  </required_header>
  <id_info>
    <org_study_id>22-PP-12</org_study_id>
    <nct_id>NCT05704920</nct_id>
  </id_info>
  <brief_title>Integrating Artificial Intelligence Into Lung Cancer Screening.</brief_title>
  <acronym>DACAPO</acronym>
  <official_title>A Randomized Controlled Study of Including a Deep Learning-based Analysis of Chest Computed Tomography as an Aid to Decision Making of Multidisciplinary Team Meetings for Lung Cancer Screening in Eligible Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nice</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nice</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Lung cancer (LC) screening using low-dose chest CT (LDCT) has already proven its efficacy.&#xD;
&#xD;
      The mortality reduction associated with LC screening is around 20%, much higher than the&#xD;
      reduction in mortality associated with screening for breast, colon or prostate cancers.&#xD;
&#xD;
      Implementing lung cancer screening on a large scale faces two main obstacles:&#xD;
&#xD;
        1. The lack of thoracic radiologists and LDCT necessary for the eligible population&#xD;
           (between 1.6 and 2.2 million people in France);&#xD;
&#xD;
        2. The high frequency of false positive screenings: in the NLST trial, more than 20% of the&#xD;
           subjects screened were found to have at least one nodule of an indeterminate lung nodule&#xD;
           (ILN) whereas less than 3% of ILNs are actually LC.&#xD;
&#xD;
      The gold standard for determining on the benign or malignant nature of a nodule is definitive&#xD;
      histology. Otherwise, the evolution of the nodule on serial thoracic imaging is a good&#xD;
      alternative. The period of indeterminacy of a nodule can be as long as 24 months in many&#xD;
      cases, which can be a source of prolonged and sometimes unjustified anxiety for screening&#xD;
      candidates.&#xD;
&#xD;
      The purpose of this randomized controlled study that focuses on LC screening in patients aged&#xD;
      50 to 80 years, who smoked more than 20 packs/ year or stopped smoking less than 15 years&#xD;
      ago. Its objective is to determine whether assisting multidisciplinary team (MDT) meetings&#xD;
      with an AI-based analysis of screening LDCT accelerates the definitive classification of&#xD;
      nodules into malignant or benign.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2023</start_date>
  <completion_date type="Anticipated">April 1, 2029</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2028</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnosis of lung disease</measure>
    <time_frame>At 3 years</time_frame>
    <description>Elapsed time between lung nodule discovery and MDT decision making.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Operating characteristics of Ai-based strategy</measure>
    <time_frame>At 3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2722</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>IA Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with at least one nodule (&gt; 6mm) for whom the multidisciplinary team meeting discussion is informed of the AI-based analysis of their chest computed tomography</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group not IA analysis</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with at least one nodule (&gt; 6mm) for whom the multidisciplinary team meeting discussion is not informed of the AI-based analysis of their chest computed tomography</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>IA</intervention_name>
    <description>The multidisciplinary team meeting discussion is informed of the AI-based analysis of their chest computed tomography</description>
    <arm_group_label>IA Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Not IA</intervention_name>
    <description>The multidisciplinary team meeting discussion is not informed of the AI-based analysis of their chest computed tomography</description>
    <arm_group_label>Group not IA analysis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age between 50 and 80 years old&#xD;
&#xD;
          -  active smoker or ex-smoker who quit smoking less than 15 years ago&#xD;
&#xD;
          -  smoking history of at least 20 pack-years&#xD;
&#xD;
          -  signature of the informed consent&#xD;
&#xD;
          -  affiliation to French social security&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  clinical signs suggestive of cancer&#xD;
&#xD;
          -  recent chest scan (&lt;1 year) for another cause&#xD;
&#xD;
          -  radiological abnormality requiring follow-up or additional investigations&#xD;
&#xD;
          -  health problem significantly limiting life expectancy from the clinician's point of&#xD;
             view&#xD;
&#xD;
          -  health problem limiting ability or willingness to undergo lung surgery&#xD;
&#xD;
          -  Patients with active neoplasia, except basal cell carcinoma of the skin.&#xD;
&#xD;
          -  vulnerable people: adults under guardianship, adults under curatorship medical and/or&#xD;
             psychiatric problems of sufficient severity to limit full adherence to the study or&#xD;
             expose patients to excessive risk&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marquette Charles-Hugo</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Nice, Service de Pneumologie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marquette Charles-Hugo, PhD</last_name>
    <phone>+33492037777</phone>
    <email>marquette.c@chu-nice.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Boutros Jacques</last_name>
    <phone>+33492037777</phone>
    <email>boutros.j@chu-nice.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU de Nice - HÃ´pital de Pasteur</name>
      <address>
        <city>Nice</city>
        <state>Alpes-maritimes</state>
        <zip>06001</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Marquette Charles-Hugo, PhD</last_name>
      <phone>+33492037777</phone>
      <email>marquette.c@chu-nice.fr</email>
    </contact>
    <contact_backup>
      <last_name>Boutros Jacques</last_name>
      <phone>+33492037777</phone>
      <email>boutros.j@chu-nice.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Marquette Charles-Hugo, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>January 19, 2023</study_first_submitted>
  <study_first_submitted_qc>January 27, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 30, 2023</study_first_posted>
  <last_update_submitted>January 27, 2023</last_update_submitted>
  <last_update_submitted_qc>January 27, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

